Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Aripiprazole Lauroxil

FDA-approved product (suspension, extended release, intramuscular), marketed as Aristada, Aristada Initio Kit.

Registered studies
10
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Aripiprazole Lauroxil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aggressive behavior
  • Agitation
  • Autism
  • Bipolar disorder
  • Bipolar I disorder
  • Depressive disorder
  • Major depressive disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia
  • Tourette syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae45.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

10registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Aripiprazole Lauroxil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Aripiprazole Lauroxil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • C-Cog in Early Course Schizophrenia Study

    NCT05662306 · start 2024-01-23

    Registered record
    Registry ID
    NCT05662306
    Conditions
    Schizophrenia
    Interventions
    Aripiprazole Lauroxil; Computerized cognitive and functional skills training
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2024-01-23
    Completion
    2025-03-03
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionAripiprazole Lauroxil; Computerized cognitive and functional skills training
    PhasePhase 4
    Registry statusTerminated

  • VA Aripiprazole vs Esketamine for Treatment Resistant Depression

    NCT05554627 · start 2023-10-27

    Registered record
    Registry ID
    NCT05554627
    Conditions
    Depressive Disorder, Major
    Interventions
    Esketamine; Aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2023-10-27
    Completion
    2023-10-27
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder, Major
    InterventionEsketamine; Aripiprazole
    PhasePhase 4
    Registry statusWithdrawn

  • Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

    NCT04203056 · start 2019-12-16

    Registered record
    Registry ID
    NCT04203056
    Conditions
    Schizophrenia; Schizoaffective Disorder, Depressive Type; Schizophreniform Disorder
    Interventions
    Aripiprazole Lauroxil; ARI-ORAL; AL-NCD
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2019-12-16
    Completion
    2022-10-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder, Depressive Type; Schizophreniform Disorder
    InterventionAripiprazole Lauroxil; ARI-ORAL; AL-NCD
    PhasePhase 4
    Registry statusTerminated

  • Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)

    NCT03919994 · start 2019-03-28

    Registered record
    Registry ID
    NCT03919994
    Conditions
    Schizophrenia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-03-28
    Completion
    2023-01-04
    Enrolment
    338

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

    NCT03345979 · start 2017-11-15

    Registered record
    Registry ID
    NCT03345979
    Conditions
    Schizophrenia
    Interventions
    Aripiprazole Lauroxil; Paliperidone Palmitate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-11-15
    Completion
    2019-03-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionAripiprazole Lauroxil; Paliperidone Palmitate
    PhasePhase 3
    Registry statusCompleted

  • A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia

    NCT02634320 · start 2015-12

    Registered record
    Registry ID
    NCT02634320
    Conditions
    Schizophrenia
    Interventions
    Aripiprazole Lauroxil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-12
    Completion
    2017-07-11
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionAripiprazole Lauroxil
    PhasePhase 4
    Registry statusCompleted

  • A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder

    NCT02636842 · start 2015-12

    Registered record
    Registry ID
    NCT02636842
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    Aripiprazole Lauroxil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-12
    Completion
    2016-06
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    InterventionAripiprazole Lauroxil
    PhasePhase 1
    Registry statusCompleted

  • An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

    NCT02320032 · start 2014-12

    Registered record
    Registry ID
    NCT02320032
    Conditions
    Schizophrenia
    Interventions
    Aripiprazole Lauroxil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-12
    Completion
    2016-04
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionAripiprazole Lauroxil
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia

    NCT01469039 · start 2011-12

    Registered record
    Registry ID
    NCT01469039
    Conditions
    Schizophrenia
    Interventions
    ALKS 9072; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-12
    Completion
    2014-03
    Enrolment
    623

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionALKS 9072; Placebo
    PhasePhase 3
    Registry statusCompleted

  • National Pregnancy Registry for Psychiatric Medications

    NCT01246765 · start 2008-11

    Registered record
    Registry ID
    NCT01246765
    Conditions
    Pregnant Women; Psychotropic Drugs
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2008-11
    Completion
    2033-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnant Women; Psychotropic Drugs
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting